DOCSLIB.ORG

Free PDF Download

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Free PDF Download European Review for Medical and Pharmacological Sciences 2020; 24: 461-468 Effects of nalmefene hydrochloride on TLR4 signaling pathway in rats with lung ischemia-reperfusion injury N.-L. ZHANG1, H.-Q. WANG2, J. YANG1, P. YANG3, P. KANG4, T. ZHAO1 1Department of Anesthesiology, People’s Hospital of Rizhao, Rizhao, P.R. China 2Operation Room, People’s Hospital of Rizhao, Rizhao, P.R. China 3Administrative District Clinic, The People’s Hospital of Zhangqiu Area, Jinan, P.R. China 4Rehabilitation Department, The People’s Hospital of Zhangqiu Area, Jinan, P.R. China Abstract. – OBJECTIVE: To investigate the ef- Introduction fect of nalmefene hydrochloride on TLR4 signal- ing pathway in rats with lung ischemia-reperfu- Ischemia-reperfusion is a phenomenon that sion injury. often occurs during major operations and or- MATERIALS AND METHODS: Altogether 64 pure inbred male SD rats were divided into gan transplantation. During this period, in the groups A, B, C, and D according to the principle reperfusion process, the tissue of specific organs of body weight similarity, with 24 rats in each will aggravate the tissue damage to specific or- group. Four groups of rats were respectively gans during reoxygenation, which is considered twisted on the left testis to establish unilateral to be more harmful than ischemia itself1. Isch- testicular torsion rats. Group A was the control emia-reperfusion injury of lung is related to lung group, treated with normal saline, group B was transplantation, extracorporeal circulation, pul- the nalmefene hydrochloride high-dose group, treated with 20 μg/kg of nalmefene hydrochlo- monary embolism extirpation, and pneumonec- ride, group C was the nalmefene hydrochloride tomy, which may lead to pulmonary dysfunction low-dose group, treated with 10 μg/kg of nalme- and serious damage. Among its pathogenesis, ox- fene hydrochloride, and group D was the sham ygen free radicals, inflammatory mediators, and operation group. Lung tissue was collected 60 neutrophils play an important role2. As the mech- h later. Western blotting was used to detect the anisms involved in lung ischemia-reperfusion in- expression levels of HMGB1, TLR4, CD14, and NF-κB protein, qPCR was used to detect the jury are complex and interrelated, showing one of mRNA expression level, and enzyme-linked im- the clear mechanisms can help prevent potential munosorbent assay (ELISA) was used to detect serious complications3. Toll-like receptor (TLR), a the expression levels of inflammatory factors pattern recognition receptor that provides the first IL-17, IL-6, and ICAM-1. line of defense against pathogens such as bacte- RESULTS: The expression levels of HMGB1, ria and viruses, is the initial site for activation of TLR4, CD14, NF-κB protein, mRNA, IL-17, IL-6, inflammatory signals in the lung during ischemia and ICAM-1 in group A were significantly high- 4 er than those in groups B, C, and D (p<0.05), and reperfusion . TLR4 plays a key role in the in- while were significantly lower in group D than in flammatory cascade of lung ischemia-reperfusion groups B and C (p<0.05), and were significantly injury. The downstream molecular nuclear fac- lower in group B than in group C (p<0.05). tor-κB (NF-κB) of the cascade is also important CONCLUSIONS: Nalmefene hydrochloride can for autoimmune regulation. The changes of var- effectively inhibit the signal pathway of TLR4, ious proinflammatory factors, chemokines, ad- and can effectively reduce the injury caused by lung ischemia-reperfusion. The large dose is hesion molecules, and enzymes involved in lung closely related to the good effect, which is wor- ischemia-reperfusion injury depend on the activa- thy of promotion. tion of NF-κB5-7. Activation of TLR4 leads to nu- clear translocation of NF-κB, which in turn leads Key Words: to an increase in the expression level of various Lung ischemia-reperfusion, Nalmefene hydrochlo- inflammatory factors, resulting in injury8,9. High ride, TLR4, CD14, NF-κB, Signal pathway. mobility group protein B1 (HMGB1) participates Corresponding Author: Tao Zhao, MD; e-mail: [email protected] 461 N.-L. Zhang, H.-Q. Wang, J. Yang, P. Yang, P. Kang, T. Zhao in many inflammatory reactions in the body and collected for examination14. Group B was a large can combine with TLR4 to promote the activation dose group of nalmefene hydrochloride. Nalme- of NF-κB, which is an important pathway leading fene hydrochloride (trade name: Jinmeifen, Yuxi to the activation of inflammatory10. However, the Pharmaceutical Co., Ltd., Lingbao, Henan prov- receptor CD14 of lipopolysaccharide can cause ince, China, specification: 1 ML: 0.1 mg, approval activation of TLR4, thus causing inflammatory number: Chinese medicine standard H20080805) reaction11. was injected intravenously 10 min before the left Drug therapy has always been a preferred pulmonary hilum was blocked. The treatment in method to regulate the signal pathway of TLR4 and other places was the same as that in Group A. reduce the injury caused by lung ischemia-reper- Group C was a small dose group of nalmefene hy- fusion. However, studies have found that opioid drochloride. A total of 20 μg/kg of namefene hy- peptides can interact with receptors on the surface drochloride (10 μg/kg) was injected intravenously of pulmonary capillary endothelial cells and play into the tail before the left lung was blocked for 10 an important role in acute lung injury12. However, min. The treatment in other places was the same some studies have shown that nalmefene hydro- as that in Group A15. Group D was a sham op- chloride, a new generation opioid receptor antag- eration group. The left hilar was dissociated by onist, has longer acting time, stronger membrane thoracotomy without clamping. At the same time, permeability, higher bioavailability, and less ad- the tail vein of each group was injected with equal verse reactions, and can effectively reduce lung volume of 0.9% sodium chloride solution. After ischemia-reperfusion injury13, so it is commonly 60 h, rats were executed, and lung tissue was ex- used in lung injury reperfusion. However, this re- tracted. search focused on mechanism analysis, and ana- lyzed the influence of nalmefene hydrochloride on Detecting of Protein Level TLR4 signal pathway in lung ischemia-reperfusion by Western Blotting injury through the rat model. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) of the same specimen was taken as an internal reference, the animals of each ex- Materials and Methods perimental group (n=6) were executed 24 h after modeling, and the lung tissues of the extracted Selection of Experimental Animals mice were placed in a refrigerator at –80°C for Sixty-four healthy male SD rats were selected, later use. Western blotting was used to detect the with SPF grade and similar age, weight, and body expressions of HMGB1, TLR4, CD14, and NF- length. The rats were from Hunan SJA Labora- κB proteins. HMGB1/GAPDH, TLR4/GAPDH, tory Animal Co., Ltd. The animal manufactur- and NF-κB/GAPDH represent the relative ex- ing license was SCXK (Hunan) 2019-0003. The pression level. laboratory feeding environment was as follows: 12 h of light, 45%-60% of relative humidity, and Detection of MRNA Expression of TLR4, 23-25°C. This study was approved by the Ethics NF-κB, HMGB1, CD14 by QPCR Committee. Extracting of total RNA Establishment of Animal Model About 50 mg of tissue was put into 1.5 ml of Sixty-four rats were randomly divided into RNAse-free centrifuge tube, 0.5 ml of TRIzol groups A, B, C, and D with 16 rats in each group was added. After being ground to homogenate by by random number table method. Group A was a homogenizer, 0.5 ml of TRIzol was added for the control group. The left porta of lung was dis- placing, and the whole process was about 0.5 h. A sociated after thoracotomy, and the occlusion was total of 200 μl chloroform was added to every 1 removed after 45 min of clamping. The swelling ml TRIzol. After rapid shaking and mixing for 30 of lung tissue was observed after 5 min. Color s, the mixture was placed on ice for 5 min. Then, recovery showed that the lung ischemia-reperfu- it was centrifuged at 4°C for 15 min at 12000 r/ sion model was successfully established. Reper- min. About 400-600 μl of supernatant was trans- fusion was continued for 2 h. Blood was collected ferred to a new centrifuge tube with a pipette gun, through the right common carotid artery. Blood then 500 μl/1 ml of TRIzol isopropyl alcohol was samples were collected and then the rats were ex- added, covered, reversed repeatedly, mixed even- ecuted, the upper lobe tissue of the left lung was ly, placed for 10 min, put into a centrifuge, and 462 Nalmefene hydrochloride in TLR4 signaling pathway in rats with lung ischemia-reperfusion injury centrifuged at 4°C for 10 min at 12000 r/min. The han Herostart Biotechnology Co., Ltd., Wuhan, supernatant was discarded, isopropyl alcohol was Hubei, China), IL-6 ELISA test kit (Shanghai absorbed. Then, 1 ml of 75% ethanol was added, Tongwei Industry Co., Ltd., Shanghai, China), and the mixture was thoroughly mixed. The RNA and ICAM-1 test kit (Shanghai Kalang Biotech- was washed after centrifuging at 4°C for 5 min nology Co., Ltd., Shanghai, China). About 100 at 10000 r/min. The supernatant was discarded, L of standard solution, sample to be tested, and dried naturally for 5-10 min, and 20 μl of DEPC negative and positive control solution were ab- water was added to fully dissolve the total RNA. sorbed into the reaction well. A total of 100 L of biological reaction antibody solution was added, qPCR covered with film, mixed, and placed for 40 min.
Load more

Recommended publications
  • Current Awareness in Clinical Toxicology Editors: Damian Ballam Msc and Allister Vale MD
    Current Awareness in Clinical Toxicology Editors: Damian Ballam MSc and Allister Vale MD February 2016 CONTENTS General Toxicology 9 Metals 38 Management 21 Pesticides 41 Drugs 23 Chemical Warfare 42 Chemical Incidents & 32 Plants 43 Pollution Chemicals 33 Animals 43 CURRENT AWARENESS PAPERS OF THE MONTH How toxic is ibogaine? Litjens RPW, Brunt TM. Clin Toxicol 2016; online early: doi: 10.3109/15563650.2016.1138226: Context Ibogaine is a psychoactive indole alkaloid found in the African rainforest shrub Tabernanthe Iboga. It is unlicensed but used in the treatment of drug and alcohol addiction. However, reports of ibogaine's toxicity are cause for concern. Objectives To review ibogaine's pharmacokinetics and pharmacodynamics, mechanisms of action and reported toxicity. Methods A search of the literature available on PubMed was done, using the keywords "ibogaine" and "noribogaine". The search criteria were "mechanism of action", "pharmacokinetics", "pharmacodynamics", "neurotransmitters", "toxicology", "toxicity", "cardiac", "neurotoxic", "human data", "animal data", "addiction", "anti-addictive", "withdrawal", "death" and "fatalities". The searches identified 382 unique references, of which 156 involved human data. Further research revealed 14 detailed toxicological case reports. Current Awareness in Clinical Toxicology is produced monthly for the American Academy of Clinical Toxicology by the Birmingham Unit of the UK National Poisons Information Service, with contributions from the Cardiff, Edinburgh, and Newcastle Units. The NPIS is commissioned by Public Health England Current Awareness in Clinical Toxicology Editors: Damian Ballam MSc and Allister Vale MD February 2016 Current Awareness in Clinical Toxicology is produced monthly for the American Academy of Clinical Toxicology by the Birmingham Unit of the UK National Poisons Information Service, with contributions from the Cardiff, Edinburgh, and Newcastle Units.
    [Show full text]
  • Opioid Antagonists As Potential Therapeutics for Ischemic Stroke
    Progress in Neurobiology 182 (2019) 101679 Contents lists available at ScienceDirect Progress in Neurobiology journal homepage: www.elsevier.com/locate/pneurobio Perspective article Opioid antagonists as potential therapeutics for ischemic stroke T ⁎ ⁎ Nadia Peyraviana,b, Emre Dikicia,b, Sapna Deoa,b, Michal Toboreka,b, , Sylvia Daunerta,b,c, a Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, USA b Dr. JT Macdonald Foundation Biomedical Nanotechnology Institute of the University of Miami, USA c University of Miami Clinical and Translational Science Institute, USA ARTICLE INFO ABSTRACT Keywords: Chronic use of prescription opioids exacerbates risk and severity of ischemic stroke. Annually, 6 million people Ischemic stroke die from stroke worldwide and there are no neuroprotective or neurorestorative agents to improve stroke out- Opioid antagonist comes and promote recovery. Prescribed opioids such as morphine have been shown to alter tight junction Blood brain barrier protein expression, resulting in the disruption of the blood brain barrier (BBB), ultimately leading to stroke Neuroprotection pathogenesis. Consequently, protection of the BBB has been proposed as a therapeutic strategy for ischemic Naloxone stroke. This perspective addresses the deficiency in stroke pharmacological options and examines a novel ap- Naltrexone plication and repurposing of FDA-approved opioid antagonists as a prospective neuroprotective therapeutic strategy to minimize BBB damage, reduce stroke severity, and promote neural recovery. Future directions discuss potential drug design and delivery methods to enhance these novel therapeutic targets. 1. Introduction modulate resulting microglia and macrophage activation in the is- chemic region to reduce neuroinflammation and prevent secondary As of 2017, the US government declared the opioid epidemic as a neurodegeneration resulting from phagocytosis of viable neurons.
    [Show full text]
  • Evidence-Based Guidelines for the Pharmacological Management of Substance Abuse, Harmful Use, Addictio
    444324 JOP0010.1177/0269881112444324Lingford-Hughes et al.Journal of Psychopharmacology 2012 BAP Guidelines BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, Journal of Psychopharmacology 0(0) 1 –54 harmful use, addiction and comorbidity: © The Author(s) 2012 Reprints and permission: sagepub.co.uk/journalsPermissions.nav recommendations from BAP DOI: 10.1177/0269881112444324 jop.sagepub.com AR Lingford-Hughes1, S Welch2, L Peters3 and DJ Nutt 1 With expert reviewers (in alphabetical order): Ball D, Buntwal N, Chick J, Crome I, Daly C, Dar K, Day E, Duka T, Finch E, Law F, Marshall EJ, Munafo M, Myles J, Porter S, Raistrick D, Reed LJ, Reid A, Sell L, Sinclair J, Tyrer P, West R, Williams T, Winstock A Abstract The British Association for Psychopharmacology guidelines for the treatment of substance abuse, harmful use, addiction and comorbidity with psychiatric disorders primarily focus on their pharmacological management. They are based explicitly on the available evidence and presented as recommendations to aid clinical decision making for practitioners alongside a detailed review of the evidence. A consensus meeting, involving experts in the treatment of these disorders, reviewed key areas and considered the strength of the evidence and clinical implications. The guidelines were drawn up after feedback from participants. The guidelines primarily cover the pharmacological management of withdrawal, short- and long-term substitution, maintenance of abstinence and prevention of complications, where appropriate, for substance abuse or harmful use or addiction as well management in pregnancy, comorbidity with psychiatric disorders and in younger and older people. Keywords Substance misuse, addiction, guidelines, pharmacotherapy, comorbidity Introduction guidelines (e.g.
    [Show full text]
  • Quadazocine Decreases Responding Reinforced by Ethanol, Sucrose, and Phencyclidine Fluid Deliveries in Rhesus Monkeys: Comparison to Naltrexone’S Effects
    Psychopharmacology (1999) 144:316–322 © Springer-Verlag 1999 ORIGINAL INVESTIGATION Keith L. Williams · Eric D. Pakarinen James H. Woods Quadazocine decreases responding reinforced by ethanol, sucrose, and phencyclidine fluid deliveries in rhesus monkeys: comparison to naltrexone’s effects Received: 24 June 1998 / Accepted: 18 February 1999 Abstract Rationale: The endogenous opioid system experiments, and thus we cannot rule out rate-dependent may mediate the reinforcing effects of ethanol as well as effects of the antagonists. sweet-tasting solutions. For example, opioid antagonists, such as naltrexone, reduce ethanol- and sucrose-rein- Key words Opioid antagonists · Alcohol reinforcement · forced responding in rhesus monkeys. If these effects are Self-administration · Primates due to blockade of the µ-receptor, then an opioid antago- nist such as quadazocine with a receptor selectivity pro- file similar to that of naltrexone should reduce respond- Introduction ing at doses correlated with its µ-selectivity. Objectives: To determine whether quadazocine would reduce re- The endogenous opioid system modulates alcohol drink- sponding for ethanol and sucrose at µ-selective doses, ing. In preclinical and clinical studies, opioid antagonists and whether quadazocine and naltrexone would reduce reduce alcohol drinking. For instance, we have previous- responding for a bitter-tasting drug solution such as ly shown that naltrexone (NTX) pretreatment in rhesus phencyclidine. Methods: Rhesus monkeys were given monkeys reduced oral ethanol self-administration access to ethanol, sucrose, or phencyclidine concurrently (Williams et al. 1998). In other studies using many dif- with water. Prior to the drinking sessions, quadazocine ferent animal species, NTX and other opioid antagonists (0.032–3.2 mg/kg) or saline was injected intramuscular- reduced oral ethanol self-administration (Levine and ly.
    [Show full text]
  • Noribogaine Is a G-Protein Biased ￃﾎￂﾺ-Opioid Receptor Agonist
    Neuropharmacology 99 (2015) 675e688 Contents lists available at ScienceDirect Neuropharmacology journal homepage: www.elsevier.com/locate/neuropharm Noribogaine is a G-protein biased k-opioid receptor agonist * Emeline L. Maillet a, , Nicolas Milon a, Mari D. Heghinian a, James Fishback a, Stephan C. Schürer b, c, Nandor Garamszegi a, Deborah C. Mash a, 1 a DemeRx, Inc., R&D Laboratory, Life Science & Technology Park, 1951 NW 7th Ave, Suite 300, Miami, FL 33136, USA b University of Miami, Center for Computational Science, 1320 S, Dixie Highway, Gables One Tower #600.H, Locator Code 2965, Coral Gables, FL 33146-2926, USA c Miller School of Medicine, Molecular and Cellular Pharmacology, 14th Street CRB 650 (M-857), Miami, FL 33136, USA article info abstract Article history: Noribogaine is the long-lived human metabolite of the anti-addictive substance ibogaine. Noribogaine Received 13 January 2015 efficaciously reaches the brain with concentrations up to 20 mM after acute therapeutic dose of 40 mg/kg Received in revised form ibogaine in animals. Noribogaine displays atypical opioid-like components in vivo, anti-addictive effects 18 August 2015 and potent modulatory properties of the tolerance to opiates for which the mode of action remained Accepted 19 August 2015 uncharacterized thus far. Our binding experiments and computational simulations indicate that nor- Available online 21 August 2015 ibogaine may bind to the orthosteric morphinan binding site of the opioid receptors. Functional activities of noribogaine at G-protein and non G-protein pathways of the mu and kappa opioid receptors were Chemical compounds studied in this article: Noribogaine hydrochloride (PubChem CID: characterized.
    [Show full text]
  • Methylenedioxymethamphetamine Therapy Be Used to Treat Alcohol Use Disorder?
    Journal of Psychedelic Studies 1(1), pp. 1–9 (2017) DOI: 10.1556/2054.01.2016.003 First published online December 27, 2016 Can 3,4,-methylenedioxymethamphetamine therapy be used to treat alcohol use disorder? BEN SESSA* Imperial College London, London, England, UK (Received: September 2, 2016; revised manuscript received: November 28, 2016; accepted: December 3, 2016) Treating people with alcohol use disorder has been an important target area for psychedelic research – both in the first studies of the 1950s and during the Psychedelic Renaissance of the last 10 years. To date, most studies have looked at the classical psychedelic drugs as adjuncts to psychotherapy; with attention paid to the psychospiritual aspect of the experience as a central therapeutic process in effecting abstinence from drinking. Psychotherapy assisted with 3,4,-methylenedioxymethamphetamine (MDMA) has never been explored for treating alcohol use disorder. However, MDMA has some unique pharmacological characteristics – particularly its capacity for reducing the fear response and facilitating engagement in therapy around past psychological trauma – that could make it a useful candidate for tackling the core features of alcohol use disorder. This paper briefly describes the burden of alcohol use disorders and the history of psychedelic-assisted psychotherapy in the field of addictions. It gives the theoretical and experimental justification for MDMA-assisted psychotherapy for treating people with alcohol use disorder and introduces a forthcoming study from Bristol and London, UK, exploring the role for MDMA in treating a person with this challenging condition. Keywords: MDMA, alcohol use disorder, dependence, psychedelic, trauma, LSD INTRODUCTION primarily on post-traumatic stress disorder (PTSD).
    [Show full text]
  • Panic Attack Following Addition of Nalmefene to Methylphenidate in A
    International Journal of Medical and Pharmaceutical Case Reports 9(3): 1-5, 2017; Article no.IJMPCR.34856 ISSN: 2394-109X, NLM ID: 101648033 Panic Attack Following Addition of Nalmefene to Methylphenidate in a Patient with Comorbid Alcohol Use Disorder and Attention Deficit Hyperactivity Disorder: A Case Report Arda Karagöl 1* 1Department of Psychiatry, Ba şkent University School of Medicine, Bahçelievler, Ankara, Turkey. Author’s contribution The sole author designed, analyzed and interpreted and prepared the manuscript. Article Information DOI: 10.9734/IJMPCR/2017/34856 Editor(s): (1) Syed A. A. Rizvi, Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, USA. Reviewers: (1) Samuel T. Gontkovsky, Wisconsin School of Professional Psychology, United States. (2) Victor Chidi Onyencho, University of Maiduguri, Nigeria. Complete Peer review History: http://www.sciencedomain.org/review-history/19821 Received 15 th June 2017 th Case Study Accepted 29 June 2017 Published 3rd July 2017 ABSTRACT Aim: Our aim is to describe a previously unreported potential interaction of nalmefene with methylphenidate and discuss possible mechanisms and precautions. Presentation of Case: A 40-year-old man with ADHD taking long-acting methylphenidate developed alcohol use disorder. Nalmefene was prescribed. Following his first bedtime administration, he awoke with panic attack symptoms and concomitant suicidal and homicidal ideation. These symptoms resolved 45 minutes after he received diazepam. Discussion: Hypotheses for this reaction include a previously undescribed nalmefene– methylphenidate interaction causing elevated levels of either drug and leading to anxiety and panic symptoms, dysphoria, and suicidal/homicidal ideation. ADHD and alcohol abuse disorder are common comorbidities and treatment with both methylphenidate and nalmefene is a reasonable approach.
    [Show full text]
  • The Effects of Nalmefene on Emotion Processing in Alcohol Use Disorder –A Randomized, Controlled Fmri Study
    European Neuropsychopharmacology (2019) 29, 1442–1452 www.elsevier.com/locate/euroneuro The effects of nalmefene on emotion processing in alcohol use disorder –A randomized, controlled fMRI study a ,1 , ∗ a ,b ,1 a Sabine Vollstädt-Klein , J. Malte Bumb , Amelie Otto , a a a ,b Christina Dinter , Damian Karl , Anne Koopmann , a ,b a a ,b Derik Hermann , Karl Mann , Falk Kiefer a Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Square J5, D-68159 Mannheim, Germany b Feuerlein Center on Translational Addiction Medicine (FCTS), University of Heidelberg, Germany Received 27 June 2018; received in revised form 13 September 2019; accepted 29 October 2019 KEYWORDS Abstract Addiction; Nalmefene is a μ- and δ-opioid receptor antagonist and a partial κ-opioid receptor agonist. Attentional bias; The drug is suggested to reduce the craving for, and the consumption of alcohol effectively, Emotion processing; also alleviating anxiety and anhedonia. The present fMRI study is the first to investigate the Dot-probe; processing of emotions as a possible mechanism of action of nalmefene in humans. Fifteen Emotional faces task; non-treatment-seeking participants suffering from alcohol use disorder (AUD) (24–66 years; 5 Opioid system females) finished this randomized, placebo controlled, double blind study. Following a cross over design, participants received either a single dose nalmefene or a placebo, with an interval of one week between sessions. Using fMRI, we investigated neural reactivity during the pre- sentation of emotional faces picture sets. Additionally, we performed a visual dot-probe task to detect nalmefene’s effects on attentional bias.
    [Show full text]
  • Revex (Nalmefene Hydrochloride Injection) Rx Only DESCRIPTION REVEX (Nalmefene Hydrochloride Injection), an Opioid Antagonist, Is a 6-Methylene Analogue of Naltrexone
    Revex (nalmefene hydrochloride injection) Rx only DESCRIPTION REVEX (nalmefene hydrochloride injection), an opioid antagonist, is a 6-methylene analogue of naltrexone. The chemical structure is shown below: Molecular Formula: C21H25NO3•HCl Molecular Weight: 375.9, CAS # 58895-64-0 Chemical Name: 17-(Cyclopropylmethyl)-4,5〈-epoxy-6-methylenemorphinan-3,14-diol, hydrochloride salt. Nalmefene hydrochloride is a white to off-white crystalline powder which is freely soluble in water up to 130 mg/mL and slightly soluble in chloroform up to 0.13 mg/mL, with a pKa of 7.6. REVEX is available as a sterile solution for intravenous, intramuscular, and subcutaneous administration in two concentrations, containing 100 µg or 1.0 mg of nalmefene free base per mL. The 100 µg/mL concentration contains 110.8 µg of nalmefene hydrochloride and the 1.0 mg/mL concentration contains 1.108 mg of nalmefene hydrochloride per mL. Both concentrations contain 9.0 mg of sodium chloride per mL and the pH is adjusted to 3.9 with hydrochloric acid. Concentrations and dosages of REVEX are expressed as the free base equivalent of nalmefene. CLINICAL PHARMACOLOGY Pharmacodynamics REVEX prevents or reverses the effects of opioids, including respiratory depression, sedation, and hypotension. Pharmacodynamic studies have shown that REVEX has a longer duration of action than naloxone at fully reversing doses. REVEX has no opioid agonist activity. REVEX is not known to produce respiratory depression, psychotomimetic effects, or pupillary constriction. No pharmacological activity was observed when REVEX was administered in the absence of opioid agonists. REVEX has not been shown to produce tolerance, physical dependence, or abuse potential.
    [Show full text]
  • Selincro, INN-Nalmefene
    Package leaflet: Information for the patient Selincro 18 mg film-coated tablets nalmefene Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Selincro is and what it is used for 2. What you need to know before you take Selincro 3. How to take Selincro 4. Possible side effects 5. How to store Selincro 6. Contents of the pack and other information 1. What Selincro is and what it is used for Selincro contains the active substance nalmefene. Selincro is used for the reduction of alcohol consumption in adult patients with alcohol dependence who still have a high level of alcohol consumption 2 weeks after the first consultation with their doctor. Alcohol dependence occurs when a person has a physical or psychological dependence on the consumption of alcohol. A high level of alcohol consumption is defined as drinking more than 60 g of pure alcohol per day for men and more than 40 g of pure alcohol per day for women. For example, a bottle of wine (750 ml; 12% alcohol by volume) contains approximately 70 g alcohol and a bottle of beer (330 ml; 5% alcohol by volume) contains approximately 13 g alcohol.
    [Show full text]
  • Cambridgeshire Nalmefene Pathway
    Peterborough Nalmefene Pathway – Responsibilities for Specialist Services & GP INTRODUCTION/BACKGROUND In November 2014 NICE (National Institute of Clinical Excellence) published the Technology Appraisal Guidance (TAG) (325): Nalmefene for reducing alcohol consumption in people with alcohol dependence. This document sets out the Nalmefene pathway for Peterborough and the clinical responsibilities for GPs, and the treatment service, following the publication of the national TAG. The Nalmefene pathway for Peterborough mirrors the pathway in CambridgEshire. INDICATION FOR USE Nalmefene (also known as Selincro®) is recommended as a possible treatment for people with alcohol dependence who: Meets the criteria with mild alcohol dependence classified as follows: Men drinking 7.5 units a day or more but less than 15 units: Women drinking 5 units a day or more but less than 12 units: no history or evidence of physical withdrawal symptoms which would require a detoxification. Agree to a programme of psychosocial support focussed on treatment adherence and reducing consumption. Continue to have a high drinking risk level 2 weeks after initial assessment. Do not need to stop drinking straight away or stop drinking completely. PRESCRIBING NALMEFENE IN PETERBOROUGH – CLINICAL RESPONSIBILITIES In Peterborough the role of prescribing Nalmefene is to be undertaken by GPs but only on the recommendation of the Drinksense (the specialist alcohol treatment service) who will provide a full assessment of a patient’s suitability and on-going support. The patient must comply with the programme of prescribing and support offered. The clinical responsibilities are set out below: The GP has the following clinical responsibilities: Referral to Drinksense where a GP identifies one of their patients may benefit from being prescribed Nalmefene.
    [Show full text]
  • Salvia Divinorum and Salvinorin A: an Update on Pharmacology And
    Oliver Grundmann Stephen M. Phipps Salvia divinorum and Salvinorin A: An Update on Immo Zadezensky Veronika Butterweck Pharmacology and Analytical Methodology Review Abstract derstand and elucidate the various medicinal properties of the plant itself and to provide the legislative authorities with enough Salvia divinorum (Lamiaceae) has been used for centuries by the information to cast judgement on S. divinorum. Mazatecan culture and has gained popularity as a recreational drug in recent years. Its potent hallucinogenic effects seen in Key words case reports has triggered research and led to the discovery of Salvia divinorum ´ Lamiaceae ´ depression ´ opioid antagonist ´ the first highly selective non-nitrogenous k opioid receptor ago- pharmacokinetics ´ pharmacology ´ toxicology ´ salvinorin A nist salvinorin A. This review critically evaluates the reported pharmacological and toxicological properties of S. divinorum Abbreviations and one of its major compounds salvinorin A, its pharmacokinet- CNS: central nervous system ic profile, and the analytical methods developed so far for its de- FST: forced swimming test tection and quantification. Recent research puts a strong empha- i.t.: intrathecal sis on salvinorin A, which has been shown to be a selective opioid KOR: kappa opioid receptor antagonist and is believed to have further beneficial properties, LSD: lysergic acid diethylamide rather than the leaf extract of S. divinorum. Currently animal norBNI: norbinaltorphimine studies show a rapid onset of action and short distribution and p.o.: per os 1039 elimination half-lives as well as a lack of evidence of short- or s.c.: subcutaneous long-term toxicity. Salvinorin A seems to be the most promising ssp.: subspecies approach to new treatment options for a variety of CNS illnesses.
    [Show full text]